article thumbnail

Viseven CEO and Co-Founder Shares Her Breast Cancer Survivor Story

Viseven

The journey that followed—filled with the courses of chemotherapy, surgeries, and radiation—tested me in ways I could never have imagined. The company’s mission to save lives by improving communication has become Nataliya’s personal guiding principle. Yet, throughout this tumultuous journey, I never once contemplated giving up.

article thumbnail

In the precision medicine era, the line between products and services is blurred

pharmaphorum

Traditionally, cancer patients are treated using “one size fits all” interventions like chemotherapy, radiotherapy and surgery. Visual communication. These tools not only make it easier to understand the service, but they can also help simplify communication and increase alignment between the many individuals engaged in the project.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

FDA drug dosage optimisation guidelines signal clinical trial reform

Pharmaceutical Technology

However, Amgen and other pharmaceutical companies have been criticised when they opted to choose the drug’s dosage based on the MTD model, which is commonly used in dose-finding trials. Impact on the industry Veal says that for a lot of pharmaceutical companies there is no “big drive to think about optimizing treatment” post-licensing.

Dosage 115
article thumbnail

FDA approves Biostar’s Phase II/III plans with utidelone injectable for NSCLC

Pharmaceutical Technology

Designated as BG01-2202, this latest trial will be an open-label, randomised, controlled clinical study of UTD1 versus chemotherapy drug docetaxel. A Phase III study to evaluate UTD1 versus docetaxel in patients that have failed chemotherapy with a platinum-containing regimen is also currently underway in China. ORR, 81.0%

FDA 52